SEATTLE, May 01, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that it will report its financial results for the first quarter of 2017 before the opening of the U.S. financial markets on Tuesday, May 9, 2017. Following the financial results announcement, members of management will host a conference call and live audio webcast to discuss the results and provide a general corporate update. Access to the conference call can be obtained as follows:
Live access on Tuesday, May 9, 2017
5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time
Telephone: +1 (877) 280-7291 (domestic) or +1 (707) 287-9361 (international)
Live webcast and replay will be available via the "Events & Presentations" page of the "News & Events" section of the Cascadian Therapeutics' website at www.cascadianrx.com.
About Cascadian Therapeutics
Cascadian Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates for the treatment of cancer. Its lead product candidate, tucatinib, is an investigational oral, selective small molecule HER2 inhibitor. Cascadian Therapeutics is conducting a randomized, double-blind controlled pivotal clinical trial called HER2CLIMB, which is comparing tucatinib vs. placebo, each in combination with capecitabine and trastuzumab, in patients with locally advanced or metastatic HER2-positive breast cancer with and without brain metastases, who have previously been treated with a taxane, trastuzumab, pertuzumab and T-DM1. Additional details on HER2CLIMB can be found at www.HER2CLIMB.com or www.clinicaltrials.gov. For more information, please visit www.cascadianrx.com.
Cascadian Therapeutics Inc. Investor and Media Contact: Monique Greer Cascadian Therapeutics 206-801-2107 email@example.com